Godshalk Welsh Capital Management Inc. Maintains Position in Bristol-Myers Squibb Company (BMY)

Godshalk Welsh Capital Management Inc. held its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the third quarter, Holdings Channel reports. The institutional investor owned 4,250 shares of the biopharmaceutical company’s stock at the end of the third quarter. Godshalk Welsh Capital Management Inc.’s holdings in Bristol-Myers Squibb Company were worth $229,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Advantus Capital Management Inc raised its stake in shares of Bristol-Myers Squibb Company by 1.0% in the third quarter. Advantus Capital Management Inc now owns 165,770 shares of the biopharmaceutical company’s stock worth $8,938,000 after buying an additional 1,653 shares in the last quarter. Chicago Partners Investment Group LLC raised its stake in shares of Bristol-Myers Squibb Company by 504.0% in the third quarter. Chicago Partners Investment Group LLC now owns 7,550 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 6,300 shares in the last quarter. Two Sigma Advisers LP bought a new stake in shares of Bristol-Myers Squibb Company during the third quarter worth $62,072,000. Lakeview Capital Partners LLC raised its stake in shares of Bristol-Myers Squibb Company by 26.6% in the third quarter. Lakeview Capital Partners LLC now owns 13,409 shares of the biopharmaceutical company’s stock worth $723,000 after buying an additional 2,819 shares in the last quarter. Finally, Saybrook Capital NC raised its stake in shares of Bristol-Myers Squibb Company by 4.3% in the third quarter. Saybrook Capital NC now owns 9,175 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 375 shares in the last quarter. 70.21% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.27% during mid-day trading on Friday, reaching $51.65. 5,845,618 shares of the company’s stock were exchanged. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $77.12. The stock has a market cap of $86.32 billion, a price-to-earnings ratio of 19.49 and a beta of 1.00. The stock’s 50-day moving average is $54.22 and its 200-day moving average is $56.43.

Bristol-Myers Squibb Company (NYSE:BMY) last announced its quarterly earnings results on Thursday, January 26th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.67 by $0.04. Bristol-Myers Squibb Company had a net margin of 22.94% and a return on equity of 31.39%. The company earned $5.24 billion during the quarter, compared to the consensus estimate of $5.14 billion. During the same period in the previous year, the firm posted $0.38 EPS. The business’s quarterly revenue was up 22.3% compared to the same quarter last year. On average, equities analysts expect that Bristol-Myers Squibb Company will post $2.81 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 1st. Stockholders of record on Friday, January 6th were issued a $0.39 dividend. The ex-dividend date of this dividend was Wednesday, January 4th. This is an increase from Bristol-Myers Squibb Company’s previous quarterly dividend of $0.38. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.02%. Bristol-Myers Squibb Company’s dividend payout ratio (DPR) is 58.87%.

COPYRIGHT VIOLATION NOTICE: This report was first posted by sleekmoney and is owned by of sleekmoney. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this report can be accessed at http://sleekmoney.com/godshalk-welsh-capital-management-inc-maintains-position-in-bristol-myers-squibb-company-bmy/1655232.html.

A number of brokerages have recently weighed in on BMY. Gabelli reaffirmed a “buy” rating on shares of Bristol-Myers Squibb Company in a research note on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and issued a $66.00 price target (down from $69.00) on shares of Bristol-Myers Squibb Company in a research note on Tuesday, January 31st. Leerink Swann reissued an “outperform” rating and set a $62.00 target price on shares of Bristol-Myers Squibb Company in a research note on Monday, January 30th. Deutsche Bank AG set a $42.00 target price on shares of Bristol-Myers Squibb Company and gave the company a “hold” rating in a research note on Friday, January 27th. Finally, Zacks Investment Research raised shares of Bristol-Myers Squibb Company from a “sell” rating to a “hold” rating in a research note on Tuesday, January 24th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $63.39.

Bristol-Myers Squibb Company Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/godshalk-welsh-capital-management-inc-maintains-position-in-bristol-myers-squibb-company-bmy/1655232.html

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *